Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
14,700 JPY | +0.93% | +2.15% | -9.73% |
04-12 | Cosmos Pharmaceutical's Attributable Profit Up 6.6% in Fiscal Nine Months | MT |
04-12 | COSMOS Pharmaceutical Corporation Provides Dividend Guidance for the Fiscal Year Ending May 31, 2024 | CI |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
- Overall, and from a short-term perspective, the company presents an interesting fundamental situation.
- The company's Refinitiv ESG score, based on a relative ranking of the company within its sector, comes out particularly poor.
Strengths
- The company is one of the most undervalued, with an "enterprise value to sales" ratio at 0.58 for the 2024 fiscal year.
- Over the last twelve months, the sales forecast has been frequently revised upwards.
- There is high visibility into the group's activities for the coming years. Outlooks on future revenues from analysts covering the equity remain similar. Such hardly dispersed estimates support highly predictable sales for the current and upcoming fiscal years.
- The group usually releases upbeat results with huge surprise rates.
Weaknesses
- The company's currently anticipated earnings per share (EPS) growth for the next few years is a notable weakness.
- The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
- The company does not generate enough profits, which is an alarming weak point.
- The company benefits from high valuations in earnings multiples.
- The valuation of the company is particularly high given the cash flows generated by its activity.
- The firm pays small or no dividend to shareholders. For that reason, it is not a yield company.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Drug Retailers
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-9.73% | 3.81B | D+ | ||
-0.73% | 3.44B | D- | ||
-23.44% | 3.15B | D | ||
+7.98% | 2.76B | - | ||
+11.98% | 2.71B | C+ | ||
-9.90% | 1.79B | - | ||
+11.26% | 1.43B | - | - | |
-20.03% | 974M | - | ||
-37.98% | 710M | - | - | |
-0.53% | 454M | - | D+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- 3349 Stock
- Ratings COSMOS Pharmaceutical Corporation